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Abstract Cardiogenic shock continues to be a life-
threatening condition carrying a high mortality and morbidity,
where the prognosis remains poor despite intensive modern
treatment modalities. In recent years, mainly technical im-
provements have led to a more widespread use of short- and
long-term mechanical circulatory support, such as veno-
arterial extracorporeal membrane oxygenation (VA-ECMO)
and left ventricular assist devices (LVADs). Currently, LVADs
are indispensable as ‘bridge’ to cardiac recovery, heart trans-
plantation (HTX), and/or as destination therapy Importantly,
both LVADs and HTX put a vast burden on financial re-
sources, besides significant short- and long-term risks of mor-
bidity and mortality. These considerations underscore the
importance of optimal timing and appropriate patient selection
for LVAD therapy, avoiding as much as possible an unfortu-
nate and costly clinical path. In this report, we present a series
of three cases with acute refractory cardiogenic shock (‘crash
and burn’, INTERMACS profile 1) successfully treated by
ECMO and early optimal medical therapy preventing a certain
path towards LVAD and/or HTX, for which they were initially
referred. This conservative approach in INTERMACS profile
one patients warrants very early introduction of adequate
medical heart failure therapy under the umbrella of a combi-
nation of short-term mechanical circulatory and inotropic
support by phosphodiesterase inhibitors. Therefore, this novel
combined medical-mechanical approach could have impor-
tant clinical implications for this extremely challenging patient
category, as it may avoid an unnecessary and costly clinical
path towards LVAD and/or heart transplantation.
Keywords Heart failure . Cardiogenic shock . LVAD .
Heart transplantation . Inodilator . INTERMACS
Introduction
Cardiogenic shock continues to be a highly dangerous condi-
tion carrying considerable risk of mortality and morbidity
despite all currently available treatment modalities. In clinical
practice, urgent resuscitation by short-termmechanical support
is often the only remaining therapeutic option to prevent a
certain death [1]. Among the available devices, veno-arterial
extra-corporeal membrane oxygenation (ECMO) has been
suggested to be the most useful initial step for urgent
stabilisation in severe, refractory cardiogenic shock [1]. More
long-term support and effective ventricular unloading is best
achieved by surgical implantation of a left ventricular assist
device (LVAD) [1]. Theoretically, high urgency heart trans-
plantation (HTX) poses an alternative strategy in the acute
setting, but is hampered by scarceness of donor organs and is
therefore virtually impossible. Currently, the use of LVADs is
increasing rapidly in popularity as ‘bridge-to-recovery’,
‘bridge-to-transplantation’, or ‘destination therapy’ [1, 2], in
the absence of generally accepted practice guidelines to aid in
optimal patient selection and cost-effectiveness. The rationale
of LVAD implantation in patients with acute refractory
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cardiogenic shock often poses an ultimate therapeutic step, but
is well known to carry a considerable morbidity and mortality.
Recently, results of the INTERMACS registry have clearly
shown that the postoperative outcome of advanced heart fail-
ure patients undergoing ventricular assist device implantation
is strongly influenced by their preoperative INTERMACS
profile [3]. INTERMACS profile one patients are defined by
cardiogenic shock with persisting haemodynamic instability in
spite of increasing doses of inotropes and IABP support with
critical hypoperfusion of target organs [3]. In that sense, it is
evident that patients suffering severe cardiogenic shock, i.e.
defined as INTERMACS profile 1, generally had a deleterious
outcome. The authors argue that their results call for a change
in policies related to the management of heart transplant and
LVAD candidates in this specific patient category due to their
deleterious outcome [3].
Here, we present an alternative therapeutic strategy, exem-
plified by a series of three cases presenting with acute, severe
and refractory cardiogenic shock and successfully treated by
early veno-arterial ECMO (Table 1). The latter was combined
with optimised medical therapy, i.e. early but gradual titration
of low-dose beta-blocker therapy under the ‘umbrella’ of
phosphodiesterase inhibitors, for a prolonged period of time.
All three patients survived the initial critical phase of severe
cardiogenic shock (‘crash and burn’, INTERMACS profile 1)
and recovered to such a degree that there was no need for other
definite and irreversible therapeutic solutions such as LVAD
implantation or heart transplantation.
Case series
Patient A
A 28-year-old male without any cardiovascular history but
known alcohol and drug (amphetamine) abuse, was admitted
to our Intensive Cardiac Care Unit with acute, severe and
refractory cardiogenic shock (Table 1). Laboratory tests re-
vealed concomitant multi-organ failure: acute kidney injury
requiring renal replacement therapy, elevated liver enzymes
and lactate levels. The electrocardiogram showed a normally
conducted sinus tachycardia (138 beats/min), and signs of left
atrial dilatation, but no ischaemia. On echocardiography, the
left ventricle was extensively dilated (left ventricular (LV)
end-diastolic diameter 68 mm) exhibiting a severely impaired
LV contractility and mild mitral regurgitation (Fig. 1a).
Coronary angiography revealed no significant lesions and
acute myocarditis and fibrosis were excluded by cardiac mag-
netic resonance imaging. Initial treatment with inotropics and
intra-aortic balloon pump (IABP) was insufficient, necessitat-
ing veno-arterial (VA) ECMO to stabilise the patient. The
patient had an INTERMACS profile 1 as defined [3]. Given
the limited maximal ECMO support duration of a few weeks,
urgent HTX or ‘bridge-to-HTX’ LVAD therapy was discussed
early but considered contraindicated due to expected noncom-
pliance related to active alcohol and drug abuse. As a possible
alternative, we decided to prolong the VA-ECMO therapy as
bridge-to-recovery and we started by introducing regular heart
failure therapy in a very early stage. This regimen included an
ACE inhibitor (ramipril) and beta blockade (bisoprolol) at the
lowest possible dosages, importantly under the umbrella of
phosphodiesterase inhibition (enoximone). Under this regi-
men, the patient survived this initial critical phase (‘crash to
certain death’) while his cardiac function and multi-organ
failure gradually improved. After 11 days of VA-ECMO, the
patient could be successfully weaned from mechanical venti-
lation and ECMO. During the following weeks, the HF treat-
ment was further intensified in dosage and the patient recov-
ered uneventfully. LV function recovered to a moderately
impaired LV function in 4 weeks. At long-term follow-up
(18 months), the patient remained asymptomatic and his LV
function remained stable (estimated EF 35–40 %) on standard
heart failure medication including bisoprolol, ramipril, digox-
in and spironolactone (Figs. 1b and 2). Thereafter, the patient
complied irregularly with his visits at our outpatient heart
failure clinic, in the end withdrawing fully from further visits.
Patient B
A 25-year-old female with no history of cardiovascular dis-
ease was admitted with severe cardiogenic shock and decom-
pensated heart failure after a week of fever, myalgia, nausea
and vomiting (Table 1). Blood results demonstrated multi-
organ failure and elevated lactate levels. Echocardiography
demonstrated biventricular dilatation with severely impaired
contractility and presence of a right ventricular (RV) intracav-
itary thrombus. Cardiogenic shock was refractory to optimal
medical treatment (high-dose inotropes) and her clinical con-
dition deteriorated rapidly. The patient had an INTERMACS
profile 1 as defined [3]. Based on the clinical presentation,
acute myocarditis was suspected as being a potentially revers-
ible underlying cause. Therefore circulatory support using VA-
ECMO was initiated. Subsequently, the diagnosis of acute
myocarditis could be confirmed by RV endomyocardial biop-
sies showing extensive lymphocytic myocardial infiltration and
evidence of recent Influenza A and parvo virus B19 infection.
During VA-ECMO therapy, alongside low-dose enoximone,
we gradually introduced bisoprolol and ramipril at low dos-
ages. The patient improved clinically and her renal function and
liver enzymes normalised. After 7 days of mechanical support,
ECMO could be weaned. The clinical course was complicated
by 3rd degree AV block necessitatingDDD-pacemaker implan-
tation. The patient’s further recovery was uneventful under
standard heart failure therapy. Enoximone could be stopped
after 16 days, and she was discharged after 36 days of hospital
admission. Regular follow-up echocardiograms showed an
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improvement in cardiac function. At 3.5 years of follow-up, she
remains fully asymptomatic with only mildly depressed LV
function with estimated ejection fraction (EF) of 40–45 %,
normal LV dimensions (LVEDD 48mm) and normal LV filling
pressures (E/E’ 8).
Patient C
A 50-year-oldmale with no relevant medical history presented
to a referring hospital with severe left-sided heart failure with
signs of dilated cardiomyopathy on echocardiography
Table 1 Patient characteristics
Patient A Patient B Patient C
Age 28 years 25 years 50 years
Gender Male Female Male
Medical history Alcohol and drug abuse None Depression
Complaints Progressive fatigue and shortness
of breath
Muscle pain, nausea, vomiting
and dizziness since 1 week
Muscle pain, subfebrile temperatures,
fatigue and stomach pain since 1 week
Admission with Acute severe heart failure, cardiogenic shock Acute severe heart failure,
cardiogenic shock
Acute severe heart failure,
cardiogenic shock
Echocardiography Severely impaired systolic LV function
with dilated left ventricle with mild mitral
insufficiency.
Severely impaired systolic LV
and RV function, thrombus in
right ventricle
Severely impaired systolic LV function,
dilated cardiomyopathy,
large LV thrombus
Additional studies Laboratory: lactate acidosis and multi-organ
failure (ATN, shock liver)
MRI showed dilated cardiomyopathy
without any signs of acute myocarditis
Laboratory: lactate acidosis and
multi-organ failure (ATN,
shock liver)








Diagnosis Refractory cardiogenic shock due to toxic
cardiomyopathy (alcohol and amphetamine)
Refractory cardiogenic shock
based on parvo B19 viral
myocarditis
Refractory cardiogenic shock
based on de novo dilated CMP e.c.i.




High-dose positive inotropes, and IABP
Therapeutic
approach
VA-ECMO short term mechanical support
Enoximone 1 mg/kg/min intravenously with








VA-ECMO short-term mechanical support
Enoximone 1 mg/kg/minintravenously with




11 days 7 days 10 days
Complications Episode of thrombocytopenia
and HIT





Acenocoumarol; Bisoprolol 10 mg qd;
Ramipril 3.75 bid; Furosemide 20 mg qd;
Esomeprazole 40 mg bid; Quetiapine
25 mg bid.
Ramipril 5 mg bid; Metoprolol
Succinate 100 mg bid;
Furosemide 40 mg qd;
Ferrofumarate 200 mg tid;
Esomeprazole 40 mg qd
Acenocoumarol; Ramipril 7.5 mg bid;
Metoprolol Succinate 50 mg bid;
Digoxin 0.125 mg qd; Amiodarone
200 mg qd; Furosemide 40 mg qd;
Spironolactone 12.5 mg qd;




4 weeks after admission: moderately
impaired systolic LV function, mild
mitral insufficiency.
5 weeks after admission: mildly
impaired systolic LV and RV
function, no signs of
thrombus or valve
insufficiency
6 weeks after admission: mildly
impaired systolic LVand RV
function, no signs of thrombus
or significant valve insufficiency
Long-term
follow-up
At 1.5 years follow-up, he is asymptomatic,
NYHA class I. Echo: estimated EF
35–40 %
At 3.5 years follow-up, she is
asymptomatic, NYHA class I.
Echo: estimated EF
40–45 %
At 2.5 years follow-up, he is
asymptomatic, NYHA class
I. Echo: estimated EF 45 %
ACEiangiotensin converting enzyme inhibitors; AVatrio-ventricular; ATNacute tubular necrosis; CMP cardiomyopathy; CVVHcontinuous veno-venous
hemofiltration; e.c.i. e causa ignota; EF ejection fraction, IABP intra-aortic balloon pump; HF heart failure; HIT heparin-induced thrombocytopenia; LV
left ventricular; RV right ventricular; MRImagnetic resonance imaging; NYHA New York Heart Association; VA-ECMO veno-arterial extra-corporeal
membraneous oxygenation
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(Table 1). He complained of myalgia, fatigue and subfebrile
temperature in the past week. Electrocardiogram revealed a
sinus tachycardia of 100 beats/min, with signs of left atrial
dilatation and LV strain pattern. Echocardiography showed a
severely impaired LV function and dilated left ventricle with
apical LV thrombus. Due to progressive cardiogenic decline
with high suspicion of fulminant myocarditis, a VA-ECMO
was implanted alongside high dosages of positive inotropics
and IABP as well as high-dose corticosteroids, immunoglob-
ulins and levosimendan. The patient had an INTERMACS
Fig. 1 a Initial phase (week 1).
Transthoracic echocardiographic
images representative of case 1;
diastolic (left) and systolic (right)
still frames from parasternal long
axis, short axis views. Side box.
LVEDD 68 mm. LVESD 62 mm.
Estimated LVEF 10 %. bAfter
ECMO and heart failure medical
treatment (6 months).
Transthoracic echocardiographic
images representative of case 1;
diastolic (left) and systolic (right)
still frames from parasternal long
axis, short axis views. Side box.
LVEDD 65 mm. LVESD 44 mm.
Estimated LVEF 35–40 %
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profile 1 as defined [3]. Because of possible candidacy for an
urgent LVAD implantation as a bridge-to-HTx, the patient was
referred to our tertiary centre. After transfer to our centre, the
IABP could be removed and inotropes were switched from
dobutamine to enoximone during VA-ECMO support. At this
stage, endomyocardial biopsy did not show active myocarditis
nor any other diagnostic clues. Therefore, the immunosuppres-
sants were stopped. Again, we introduced low-dosemetoprolol
and ramipril while continuing enoximone therapy and VA-
ECMO circulatory support. After 10 days of VA-ECMO sup-
port, the patient could be successfully weaned from mechani-
cal support. With continuing low-dose enoximone his heart
failure therapy was further optimised by increasing the dose of
metoprolol and ramipril. After 2 weeks of admission the pa-
tient improved further; also the enoximone could be stopped
and standard heart failure therapy was titrated. The patient fully
recovered and was transferred in a stable clinical condition to
the referring hospital. Regular follow-up echocardiograms
demonstrated a gradual improvement in cardiac function to
moderately impaired LV function without significant valvular
insufficiency and the apical thrombus had vanished. After
2.5 years of follow-up the patient remained asymptomatic with
mildly impaired LV function with an estimated of EF 45 %.
Discussion
Here, we present a series of cases with acute, severe and
refractory cardiogenic shock, successfully treated with
‘short-term’ ECMO support and optimised medical therapy
preventing a certain path towards LVAD and/or heart trans-
plantation. Importantly, this more conservative approach in
INTERMACS profile 1 incorporates early introduction of
heart failure therapy, already during ECMO, using
phosphodiesterase inhibition as an ‘umbrella’ to allow early
initiation of oral heart failure therapy including beta blockers
and angiotensin enzyme inhibitors.
We hypothesised that the very early initiation of medical-
mechanical support and introduction of heart failure medication
(under the umbrella of enoximone) provides themomentum for
these patients to survive the first critical phase (crash to certain
death) and afterwards continue in the upward line of clinical
recovery, thereby preventing the path towards LVAD or HTX.
Cardiogenic shock remains a highly dangerous condition
with a high risk of mortality and morbidity despite extensive
current medical and mechanical support [1–3]. With increas-
ing availability of short mechanical circulatory support and
long-term solutions such as left ventricular assist devices
(LVADs), therapeutic options in cardiogenic shock patients
are increasingly broadened [3–6]. ECMO is reported to be
successful as a bridge-to-recovery in out-of-hospital patients
presenting with severe cardiogenic shock [4–6]. With current
technological improvements, ECMO has developed into a
lightweight portable and reliable device which, in experienced
hands, is easily implanted percutaneously via the femoral
vessels in 15 min. It is therefore more applicable in acute
settings (cardiogenic shock) and the best available short-
term mechanical support device which can be used on a
temporary basis (removed easily). As a long-term solution,
the path of LVAD and/or HTX still has major drawbacks with
huge impact on financial resources [3–6]. Additionally, there
is an extreme shortage of suitable heart donors, and a signif-
icant morbidity and mortality with LVAD implantation. This
warrants some precautions and discussion on the best timing
and right patient selection before turning into an irreversible
pathway. Therefore, we question whether LVADs are the best
choice in all and we advocate that we keep trying to think of a
way to divert the path of LVAD or HTX waiting list in these
patient groups, especially in the first weeks to evaluate wheth-
er the patient can rather recover with ECMO bridging. Our
case series shows that short-term mechanical support is suit-
able as bridge-to-decision in order to identify the right candi-
dates for LVAD or HTX. Current ESC guidelines on the
diagnosis and treatment of heart failure are brief on the topic
of mechanical assist devices due to the lack of evidence and
clinical data, and clinical expert opinion is still important,
which makes our case series clinically relevant as well as the
discussion it provokes, aimed to improve patient care in this
vulnerable subset of patients.
In this case series, we discuss an alternative approach in
selected patients with severe cardiogenic shock to use a VA-
ECMO as bridge-to-recovery, enhanced by introducing very
early heart failure medication, including ACE inhibitors and
beta blockers using enoximone and ECMO. Our approach of
using VA-ECMO for a prolonged period of time under the
umbrella of enoximone therapy is new and could be a way to
prevent the bridge-to-destination or bridge-to-transplantation
Fig. 2 Serial NTproBNP levels in case 2 from presentation with cardio-
genic shock to ECMO introduction at day 2 (total VA-ECMO time
7 days), including enoximone (total time 16 days) and heart failure
medication with rapidly declining NTproBNP levels in line with clinical
recovery (discharge in good condition after 36 days)
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paths. The current approach has worked for several of our
patients with great success, as presented in our case series.
However, patient numbers (and experience) in this category
will remain small and dependent largely on clinical experi-
ence. We believe that –in our centre- this approach was partly
feasible due to the unique cooperation of cardiac intensive
care specialists as well as heart failure specialists in a com-
bined intensive care unit and cardiac care unit.
The proposed period of bridging with VA-ECMO and very
early introduction of heart failure therapy (including beta
blockers) under the umbrella of enoximone, can give the
needed time to evaluate the clinical course of the patient’s
illness and select the appropriate patients to either await clin-
ical recovery or proceed to LVAD. After stabilisation,
enoximone provided the necessary back-up to introduce B1-
selective beta blockers as these agents are independent of beta-
receptor signalling and beta receptors in contrast to dobuta-
mine [7, 8]. The site of action of phosphodiesterase inhibitors
is beyond the beta-adrenergic receptor and the two agents
have additive effects [7, 8]. We argue that the early introduc-
tion of beta-blocker therapy is essential in the recovery phase.
A gradual increase of the beta-blocker dose under the safety of
enoximone and VA-ECMOwill avert the feared haemodynam-
ic compromise [7, 8] and save enormous time in patient recov-
ery (which depends on introduction of heart failure therapy).
Still, the early introduction of beta-blocker therapy seems
contra-intuitive and is challenged by other experts [7, 8].
In all three patients, cardiogenic shock and multi-organ
failure persisted despite conventional support which was the
reason to expand treatment with VA-ECMO rapidly as an
option for short-term (temporary) mechanical support. The
choice for VA-ECMO depends on experience and device
availability in the centre. VA-ECMO can be inserted – percu-
taneously – rapidly and buy time. It is essential to take this
decision as early as possible on the first day, before multi-organ
failure has advanced to such a degree that VA-ECMO is also
doomed to fail. Realistically, some patients will cope
(as presented in the current cases), but others will not and still
need LVAD or heart transplantation despite all efforts [9]. VA-
ECMO can be removed and is a temporary device. The
INTERMACS study taught us that patients in cardiogenic
shock have a deleterious outcome with urgent LVAD implan-
tation and these results call for a change in management in this
particular patient category, Therefore, our conservative regi-
men targets INTERMACS profile 1 patients and may provide
us with the valuable time to evaluate this patient category for
proper selection. In our opinion this should be attempted, as an
‘LVAD for all’ approach is detrimental to these patients with
INTERMACS profile 1 [3] as well as not manageable on a
large scale. While searching for alternative treatment, we real-
ise that our regimen requires a high dedication and patience
from the whole clinical team. The current regimen should be
tested in larger studieswhichmay providemore insight into the
best applicable patients as well as the effect of the underlying
cause of acute heart failure on decision-making.
In conclusion, we advocate an initial conservative
approach in INTERMACS profile 1 patients by combining
short-termmechanical circulatory support with early introduc-
tion of medical heart failure therapy under the umbrella of
phosphodiesterase inhibitors, which could be a successful way
to treat refractory cardiogenic shock patients. This novel ap-
proach may have clinical implications as it shows that the
clinical path towards LVAD and/or heart transplantation can
be diverted in some, whichmakes the discussion on applicable
patients for LVADs even more challenging and efforts to
reduce unnecessary LVAD implantation evenmore warranted.
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